Navigation Links
TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
Date:5/1/2008

- Research Published in March Issue of Journal of Experimental Medicine - - Findings Underscore Versatility of TorreyPines' AMPA/Kainate Receptor

Antagonists as Possible Antithrombotic Agents -

LA JOLLA, Calif., May 1 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has signed an exclusive license agreement with Johns Hopkins University (JHU) for intellectual property related to the novel use of glutamate receptor antagonists, including the company's lead compounds tezampanel and NGX426, for the prevention and treatment of stroke, heart attack and other conditions associated with increased platelet aggregation. Financial terms of the license agreement were not disclosed.

The intellectual property is based on research conducted in the JHU laboratories of Craig Morrell, D.V.M., Ph.D., and Charles Lowenstein, M.D., that demonstrates the importance of glutamate release in promoting platelet activation and thrombosis and which identifies the AMPA receptors on platelets as a new antithrombotic target. Published in the March issue of The Journal of Experimental Medicine, the research shows that platelets treated with an AMPA receptor antagonist are more resistant to agonist-induced aggregation than untreated platelets. The studies also show that mice treated with an AMPA receptor antagonist have a prolonged time to clot formation and blood vessel occlusion compared with control mice.

"This is breakthrough research that further illustrates the importance of glutamate receptors as a new target for a wide range of indications," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "Additionally, the findings underscore the versatility and co
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
2. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
3. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
4. Transition Therapeutics to Present at 2008 Morgan Stanley Global Healthcare Unplugged Conference
5. Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace(TM)
6. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
7. CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday, April 25, 2008
8. Precision Therapeutics Adds 8 Million Covered Lives Under Contract
9. Hyperion Therapeutics Elects Lota Zoth to Board of Directors
10. Antisense therapeutics scientist out to pull more big deals
11. Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Westlake Village, CA (PRWEB) September 23, 2014 ... Sedation Dental Office is now offering complimentary oral sedation ... about 15 percent of Americans suffer from dental anxiety ... merely uncomfortable for patients; they can also keep patients ... dental anxiety or phobia in Westlake Village and surrounding ...
(Date:9/23/2014)... September 23, 2014 PM360, a leading ... the pharmaceutical industry with their annual Trailblazer Awards on ... gala banquet at Gotham Hall in New York City, ... representing top talent and brands. , ... says Anna Stashower, CEO and Publisher of PM360. “We ...
(Date:9/23/2014)... 23, 2014 Kenall Manufacturing, a ... its MedMaster™ M4 product line with a new ... M4 product line – currently available with 2'×2' ... providing more flexibility when designing lighting for the ... M4 Series include:, •Three sizes available to ...
(Date:9/23/2014)... Rockville, MD (PRWEB) September 23, 2014 ... a proposal by the World Health Organization (WHO) regarding ... , USP supports the effort by the Expert Group ... develop a consensus-based global approach to the naming of ... principles critical to the quality assessment of these drugs. ...
(Date:9/23/2014)... 2014 Catalent Pharma Solutions, ... technologies and development solutions for drugs, biologics ... it had reached an exclusive development and ... Cingulate Therapeutics (CTx), to support the development ... products for the treatment of Attention Deficit/Hyperactivity ...
Breaking Medicine News(10 mins):Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 2Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 4Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 5Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 6Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3Health News:USP Comments to WHO Regarding Biologics Qualifier Proposal 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 3
... HOUSTON - A $4 million, five-year grant from the ... Networks Program Center (CNPC), called Latinos Contra El Cancer, ... The center is a joint project of The ... School of Public Health and The University of Texas ...
... low-dose radiation from cardiac imaging and other procedures after ... of cancer, found a new study published in ... link only) http://www.cmaj.ca/embargo/cmaj100463.pdf . The use of ... (CT) angiography and nuclear scans, is increasing which has ...
... of Sweden decided to introduce a special blessing for ... making a distinction between genuine homosexuality and promiscuous homosexuality, ... a new thesis in religious studies at the University ... between opponents and supporters of the decision. "It ...
... rates continue to rise, University of Missouri researchers are ... an effective and inexpensive way for people with addictive ... Matthew Martens, associate professor of Educational, School and Counseling ... team of researchers received a $172,500 grant from ...
... produced by the DNA of tumor cells, researchers have ... new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists ... of a drug that blocks the protein,s activity. ... target for high-risk neuroblastoma," said pediatric oncologist Kristina A. ...
... two new works, an anthropologist tackles a perplexing question relating ... tolerate and even celebrate the public display of ... of Real Human Bodies " is the most widely attended ... professor of anthropology at the University of Illinois and author ...
Cached Medicine News:Health News:Project connects researchers, Latino communities to prevent cancer 2Health News:Project connects researchers, Latino communities to prevent cancer 3Health News:Risk of cancer increases with exposure to low-dose radiation 2Health News:Supporters and opponents of a special blessing for homosexuals share many values 2Health News:Simple feedback could be effective therapy for addictive behaviors 2Health News:Protein may be key to new treatment in a childhood cancer 2Health News:Protein may be key to new treatment in a childhood cancer 3Health News:Anthropologist: 'Body Worlds' visitors confront bodies but not death 2Health News:Anthropologist: 'Body Worlds' visitors confront bodies but not death 3
(Date:9/23/2014)... , Sept. 23, 2014 Today, DripDrop, the ... the formation of the DripDrop Foundation, with its ... dehydration worldwide. Utilizing scientific advancements in Oral Rehydration ... to reduce dehydration and healthcare costs through strategic ... "DripDrop has been used in ...
(Date:9/23/2014)... , Sept. 23, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... new additions to its Scientific Advisory Board.  The new ... Anthony Davies , PhD. Dr. Acker is ...
(Date:9/22/2014)... BARCELONA , España, September 23, 2014 ... nube permite que los patrocinadores de ensayos clínicos satisfagan ... a la accesibilidad y exhaustividad de los expedientes permanentes ... La mayor encuesta sobre TMF en el ... un aumento en el número de patrocinadores de ensayos ...
Breaking Medicine Technology:DripDrop Forms Foundation To Scale Relief Efforts 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 2El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 3El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 4El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 5
... Mont., May 8, 2012  Bacterin International Holdings, Inc. ... in the development of revolutionary bone graft material ... third national GPO contract, a three-year agreement with ... and contracting company.  The agreement provides Bacterin,s full ...
... Heska Corporation (NASDAQ: HSKA ), a provider ... announced that its Board of Directors has declared a cash ... payment will be distributed on July 10, 2012 to stockholders ... to pay a regular quarterly dividend of $0.10 per share ...
Cached Medicine Technology:Bacterin International Signs Its Third National GPO Contract with Novation 2Bacterin International Signs Its Third National GPO Contract with Novation 3Bacterin International Signs Its Third National GPO Contract with Novation 4Heska Announces Quarterly Dividend of $0.10 Per Share 2
QualCraft™ Radiation Protection Eyewear providex maximum comfort and eye protection! Lenses made of 0.75 mm leaded glass. Side shields of 0.30 mm leaded acrylic help seal out scatter radiation ...
Clip-On Glasses clip onto regular eyewear frames. Plano (nonprescription) only. Will not fit over high-plus or high-minus presciptions, or over glasses with thick frames. Black wire frames. Wt. 63 g....
Qualcraft™ Radiation Readers, Wraparound Glasses. Protect yourself and have close-vision clarity....
The Bronze Metalite Constructed of optical-grade steel with bronze electroplate. Fitted lead side shields that create a seal to the front of the lenses for increased scatter protection....
Medicine Products: